Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11433164 | 0.87 | ALDH1A1 (0.57) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL11393201 | 0.85 | HDAC1 (0.58) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL11388939 | 0.84 | SMN1; SMN2 (0.56) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL12789241 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL13940677 | 0.80 | ALDH1A1 (0.53) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL12789677 | 0.77 | CYP11B1 (0.52) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL12790145 | 0.77 | LMNA (0.53) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL12790148 | 0.77 | LMNA (0.53) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL17099417 | 0.76 | LMNA (0.54) | ALDH1A1CYP11B1CYP11B2LMNARECQL | |
| SCHEMBL12790138 | 0.76 | CYP11B1 (0.48) | ALDH1A1CYP11B1CYP11B2LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | ALDH1A1 259/4885SIGMAR1 1928/4885CYP11B1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.